{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-03-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Athens",
      "state": "OH",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "81316",
      "recalling_firm": "RXQ Compounding LLC",
      "address_1": "340 W State St Unit 9",
      "address_2": "N/A",
      "postal_code": "45701-1564",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "U.S.A. nationwide",
      "recall_number": "D-0130-2019",
      "product_description": "Lidocaine 1% + Epinephrine 1:100,000 (MDV) INJ SOL, 50 mL per glass vial, Rx only, 340 West State Street, Unit 9, Athens, OH 45701.  NDC  7073197450",
      "product_quantity": "395 vials",
      "reason_for_recall": "Subpotent drug: During testing of the retention sample, the firm discovered that the product was sub-potent.",
      "recall_initiation_date": "20180925",
      "center_classification_date": "20181101",
      "termination_date": "20221018",
      "report_date": "20181031",
      "code_info": "Lot# 04042018:58, Exp 10/17/18"
    }
  ]
}